Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab

05.11.2023 - - Response observed as early as week 1 and durable for up to 16 weeks -- Data support important role for mast cells in the pathogenesis of PN and potentially other chronic itch indications -- Phase 2 PN study to initiate in early 2024 -- Conference ...

Related Keywords

Anthony Marucci ,Sarah Cavanaugh ,Martin Metz ,Celldex Therapeutics ,Corporate Affairs Administration ,Celldex Therapeutics Inc ,Company Contact ,Chief Executive Officer ,Barzolvolimab Phase ,Prurigo Nodularis Study ,Worst Itch Numerical Rating Scale ,Investigator Global Assessment ,Private Securities Litigation Reform Act ,Vice President ,Corporate Affairs ,